Genelux Announces Interim Results From Two Ongoing Trials, Phase 1b/2 SCLC And Phase 2 VIRO-25, Evaluating Systemic Administration Of Olvi-Vec In Patients With Progressive SCLC And NSCLC

-- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; enrollment ongoing –

-- In platinum-relapsed or platinum-refractory advanced SCLC, two of three partial responses (PRs) occurred in the highest dose cohort tested as of the data review cutoff date (tumor shrinkage of ~55% and ~85%), with three PRs out of nine subjects (33%) across all dose cohorts; observed durable response signals and treatment tolerability (Phase 1b/2 SCLC) --

-- In advanced or metastatic recurrent NSCLC, observed anti-tumor activity in initial dose cohort and Olvi-Vec generally well tolerated (Phase 2 VIRO-25) --

-- Additional systemic lung cancer data expected throughout 2026, alongside topline data from Phase 3 ovarian cancer trial (OnPrime/GOG-3076) in second half of 2026 --

WESTLAKE VILLAGE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced interim results from two ongoing trials – Phase 1b/2 SCLC and Phase 2 VIRO-25 - evaluating systemic (intravenous) administration of Olvi-Vec in patients with progressive small cell lung cancer (SCLC) and progressive non-small cell lung cancer (NSCLC), respectively, after failure of prior platinum-based regimens.

Together, the open-label studies are designed to demonstrate that the Olvi-Vec-primed immunochemotherapy mechanism of resensitizing tumors to platinum-based chemotherapy can extend beyond intraperitoneal delivery into a systemic delivery setting across multiple solid tumor types.